Clinical trials: Skin Infections, Bacterial
- Condition Skin Infections, Bacterial
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Viral Hepatitis Vaccines, Hepatitis A
Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis
The purpose of this study is to determine the seroprevalence of Hepatitis A Virus (HAV), Varicella-Zoster virus (VZV), Cytomegalovirus (CMV), Herpes Simplex (HSV) and Bordetella pertussis (BP)infections in Mexico.
- Conditions
- Viral Hepatitis Vaccines, Hepatitis A, Cytomegalovirus, Varicella-Zoster Virus
- Trial name
- NCT01160081
- Testing
- Serum sample
- Where
- Mexico
- Volunteers
- 3,658 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Impetigo
Fucidin® Cream in the Treatment of Impetigo
To investigate the clinical and bacteriological efficacy of Fucidin® cream in the treatment of impetigo in paediatric patients. To assess the validity of in vitro susceptibility-testing of S.
- Trial name
- NCT00986856
- Testing
- Fucidin® cream
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 58 people
- Sponsor
- LEO Pharma
Skin Infections, Bacterial
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
- Trial name
- NCT00555061
- Testing
- Retapamulin Ointment, 1%
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Skin Infections, Bacterial
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.
- Trial name
- NCT00133874
- Testing
- SB-275833 ointment, 1%
- Where
- 69 sites in Canada, Costa Rica and 8 more
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Tinea Pedis
Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis
To demonstrate comparable safety and efficacy of Taro Pharmaceuticals Inc. butenafine hydrochloride cream 1% (test product) and Lotrimin Ultra® cream (reference listed drug) in the treatment of interdigital tinea pedis, and to…
- Trial name
- NCT00835510
- Testing
- Butenafine cream 1% manufactured by Taro, Lotrimin Ultra (butenafine) 1%, Butenafine Vehicle manufactured by Taro
- Where
- 17 sites in United States, Belize
- Volunteers
- 548 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Capitis
A Study Of Diflucan In Children With Ringworm Of The Scalp
The purpose of this study is to evaluate the safety and efficacy of fluconazole for the treatment of tinea capitis in pediatric patients aged 3 to 12 years.
- Trial name
- NCT00645242
- Testing
- fluconazole
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 185 people
- Sponsor
- Pfizer
Acute Bacterial Skin and Skin Structure Infections
Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Phase 3, randomized, double-blind, multi-center efficacy and safety study to evaluate an oral CEM-102 loading dose regimen compared to oral linezolid in the treatment of subjects with ABSSSI
- Trial name
- NCT02570490
- Testing
- sodium fusidate, linezolid
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Arrevus Inc.
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
- Trial name
- NCT06958211
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 107 sites in United States, Belgium and 7 more
- Volunteers
- 573 people
- Sponsor
- Incyte Corporation
Tinea Pedis, Tinea Cruris
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence…
- Conditions
- Tinea Pedis, Tinea Cruris, Tinea Corporis
- Trial name
- NCT01349998
- Testing
- Product 33525
- Where
- 24 sites in United States, Belize and 3 more
- Volunteers
- 604 people
- Sponsor
- Tinea Pharmaceuticals
Impetigo
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
This is a randomized, double-blind study comparing 0.1% NVC-422, 0.5% NVC-422 and 1.5% NVC-422 topical gel in children with impetigo.
- Trial name
- NCT01367314
- Testing
- NVC-422
- Where
- 2 sites in Dominican Republic
- Volunteers
- 129 people
- Sponsor
- NovaBay Pharmaceuticals, Inc.
Skin Infections, Bacterial
ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
This is an open label, multi-centre, non-interventional post-marketing surveillance.
- Trial name
- ALTARGOPMS (NCT01445600)
- Testing
- ALTARGO(retapamulin)
- Where
- South Korea
- Volunteers
- 3,612 people
- Sponsor
- GlaxoSmithKline
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT06799000
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Onychomycosis, Tinea Unguium
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
This was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5% topical solution in treating distal subungual onychomycosis (a fungal infection) of the toenail in children and adolescents (ages 6 to 16…
- Trial name
- NCT03405818
- Testing
- Tavaborole 5% Topical Solution
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pfizer
Skin Infections, Bacterial
United States Pharmacovigilence Retapamulin-Prescribing
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the United States (US), retapamulin is approved for the treatment of impetigo in persons nine or more…
- Trial name
- NCT01153880
- Testing
- Retapamulin, Co-prescription of retapamulin and topical mupirocin
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Impetigo
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.
- Trial name
- NCT00133848
- Testing
- SB-275833 ointment, 1%
- Where
- 22 sites in India, Italy and 3 more
- Volunteers
- 210 people
- Sponsor
- GlaxoSmithKline
Non-bullous Impetigo
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
The purpose of this study is to determine the efficacy of the topical antibiotic LTX-109 in terms of clinical and microbiological response in treatment of impetigo.
- Trial name
- NCT01803035
- Testing
- LTX-109 1 %, LTX-109 2 %
- Where
- 2 sites in Dominican Republic
- Volunteers
- 210 people
- Sponsor
- Lytix Biopharma AS
Tinea Pedis
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
The objective of this study is to demonstrate that Oxiconazole nitrate 1% topical cream is effective for the treatment of patients with moderate to severe Tinea pedis.
- Trial name
- NCT01519752
- Testing
- Oxiconazole Nitrate Cream 1%, Oxiconazole Nitrate Cream 1% (Oxistat®)
- Volunteers
- 661 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Impetigo
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary nonbullous or bullous impetigo.
- Trial name
- NCT03429595
- Testing
- ATx201, ATx201 GEL Vehicle
- Where
- 16 sites in South Africa
- Volunteers
- 210 people
- Sponsor
- UNION therapeutics
HIV Infections, Histoplasmosis
A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.
- Conditions
- HIV Infections, Histoplasmosis, Blastomycosis
- Trial name
- NCT00002159
- Testing
- Itraconazole, Amphotericin B
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Janssen, LP